No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Boundless Bio Inc. Shifts Corporate Updates to IR Website
Boundless Bio, Inc. Q1 Loss Climbs
Boundless Bio | 10-Q: Quarterly report
Express News | Boundless Bio Inc: First Patient Dosed in Phase 1/2 Starmap Clinical Trial of Bbi-825 in Patients With Tumors With Resistance Gene Amplifications
Express News | Boundless: Bbi-355 Phase 1/2 Potentiate Clinical Trial Ongoing;Initiated Therapy Combinations for Tumors With Egfr/Fgfr Oncogene Amplifications
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
No Data